Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Emerging therapies for ulcerative colitis.
Hanzel J, Hulshoff MS, Grootjans J, D'Haens G. Hanzel J, et al. Among authors: grootjans j. Expert Rev Clin Immunol. 2022 May;18(5):513-524. doi: 10.1080/1744666X.2022.2069562. Epub 2022 May 1. Expert Rev Clin Immunol. 2022. PMID: 35477319 Review.
Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study.
Straatmijer T, Biemans VBC, Visschedijk M, Hoentjen F, de Vries A, van Bodegraven AA, Bodelier A, de Boer NKH, Dijkstra G, Festen N, Horjus C, Jansen JM, Jharap B, Mares W, van Schaik FDM, Ponsioen C, Romkens T, Srivastava N, van der Voorn MMPJA, West R, van der Woude J, Wolvers MDJ, Pierik M, van der Meulen-de Jong AE, Duijvestein M; Initiative on Crohn and Colitis. Straatmijer T, et al. Clin Gastroenterol Hepatol. 2023 Jan;21(1):182-191.e2. doi: 10.1016/j.cgh.2022.04.038. Epub 2022 May 26. Clin Gastroenterol Hepatol. 2023. PMID: 35644343 Free article.
Real-world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases.
Volkers A, Straatmijer T, Duijvestein M, Sales A, Levran A, van Schaik F, Maljaars J, Gecse K, Ponsioen C, Grootjans J, Hanzel J, Tack G, Jansen J, Hoentjen F, de Boer N, van der Marel S, Dijkstra G, Oldenburg B, Löwenberg M, van der Meulen A, D Haens G; IBD center Amsterdam and the Dutch Initiative on Crohn and Colitis. Volkers A, et al. Among authors: grootjans j. Aliment Pharmacol Ther. 2022 Sep;56(6):1044-1054. doi: 10.1111/apt.17153. Epub 2022 Jul 23. Aliment Pharmacol Ther. 2022. PMID: 35869807 Free PMC article.
Overexpression of Transmembrane TNF Drives Development of Ectopic Lymphoid Structures in the Bone Marrow and B Cell Lineage Alterations in Experimental Spondyloarthritis.
Kaaij MH, Rip J, Jeucken KCM, Kan YY, van Rooijen CCN, Saris J, Pots D, Frey S, Grootjans J, Schett G, van Duivenvoorde LM, Nolte MA, Hendriks RW, Corneth OBJ, van Hamburg JP, Baeten DLP, Tas SW. Kaaij MH, et al. Among authors: grootjans j. J Immunol. 2021 Nov 1;207(9):2337-2346. doi: 10.4049/jimmunol.2100512. Epub 2021 Sep 24. J Immunol. 2021. PMID: 34561228
Endoplasmic reticulum stress in the intestinal epithelium initiates purine metabolite synthesis and promotes Th17 cell differentiation in the gut.
Duan J, Matute JD, Unger LW, Hanley T, Schnell A, Lin X, Krupka N, Griebel P, Lambden C, Sit B, Grootjans J, Pyzik M, Sommer F, Kaiser S, Falk-Paulsen M, Grasberger H, Kao JY, Fuhrer T, Li H, Paik D, Lee Y, Refetoff S, Glickman JN, Paton AW, Bry L, Paton JC, Sauer U, Macpherson AJ, Rosenstiel P, Kuchroo VK, Waldor MK, Huh JR, Kaser A, Blumberg RS. Duan J, et al. Among authors: grootjans j. Immunity. 2023 May 9;56(5):1115-1131.e9. doi: 10.1016/j.immuni.2023.02.018. Epub 2023 Mar 13. Immunity. 2023. PMID: 36917985
The unfolded protein response in immunity and inflammation.
Grootjans J, Kaser A, Kaufman RJ, Blumberg RS. Grootjans J, et al. Nat Rev Immunol. 2016 Aug;16(8):469-84. doi: 10.1038/nri.2016.62. Epub 2016 Jun 27. Nat Rev Immunol. 2016. PMID: 27346803 Free PMC article. Review.
55 results